Leaderboards/Hidradenitis Suppurativa and Treatments

Hidradenitis Suppurativa and Treatments

Last updated July 7, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Sophie Glatt
UCB Pharma (Belgium)
2
Fabrizio Martora
Federico II University Hospital
3
Shanthi Narla
Medical College of Wisconsin
4
Dillon Mintoff
Mater Dei Hospital
5
Carmen Liy‐Wong
Children's Hospital of Eastern Ontario
6
Justine R. Seivright
University of California, Los Angeles
7
Michela Iannone
University of Pisa
8
Victoria E. Orfaly
Oregon Health & Science University
9
James M. Kilgour
Cardiff University
10
Paula Rosa Coutinho Goulart Borges Mariottoni
Universidade Estadual Paulista (Unesp)

Rising Stars Papers

1
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
Clinical Cosmetic and Investigational Dermatology|2024
40 cit.
2
Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
Journal of Dermatological Treatment|2024
10 cit.
3
Differences in hidradenitis suppurativa patterns of cutaneous involvement between sexes: Insights from a cross-sectional study
Human Immunology|2024
6 cit.
4
Attitudes towards disclosure of familial genetic risk in a Mediterranean island population – A survey of the Maltese population
European Journal of Medical Genetics|2024
5 cit.
5
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient
Dermatology and Therapy|2025
5 cit.
6
Unaddressed Challenges in the Treatment of Cutaneous Melanoma?
Medicina|2024
4 cit.
7
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report
Clinical Cosmetic and Investigational Dermatology|2024
2 cit.
8
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report
Clinical Cosmetic and Investigational Dermatology|2024
2 cit.
9
From sunbeds to sunscreen: A curriculum empowering oregon adolescents to take charge of their skin health
Journal of the American Academy of Dermatology|2024
2 cit.
10
JAAD CME Part 2: Clinical Evidence and Safety Considerations for GLP-1 Receptor Agonists in Dermatology
Journal of the American Academy of Dermatology|2026
2 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Andrew Strunk
Northwell Health
2
Alejandro Molina‐Leyva
Universidad de Granada
3
Elisa Muscianisi
Gene Therapy Laboratory
4
Alexander Egeberg
University of Copenhagen
5
Vivian Y. Shi
University of Washington
6
Allireza Alloo
New York University
7
A.A. Salad
Unknown
8
Virginia Sanz‐Motilva
Hospital de Manises
9
Claudio Marasca
Ospedale Antonio Cardarelli
10
Amanda S. MacLeod
Janssen (Belgium)

Emerging Leaders Papers

1
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
The Lancet|2023
302 cit.
2
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)
Journal of the American Academy of Dermatology|2022
93 cit.
3
Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries
Seminars in Arthritis and Rheumatism|2022
87 cit.
4
Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)
The Lancet Regional Health - Europe|2023
41 cit.
5
Potential Benefits of the Mediterranean Diet and Physical Activity in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study in a Spanish Population
Nutrients|2022
40 cit.
6
Hidradenitis suppurativa flares following COVID-19 vaccination: A case series
JAAD Case Reports|2022
39 cit.
7
A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa?
Skin Appendage Disorders|2022
32 cit.
8
Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study
Dermatology and Therapy|2023
30 cit.
9
Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
Journal of Clinical Medicine|2022
27 cit.
10
Sexual Dysfunction and Quality of Life in Patients with Hidradenitis Suppurativa and Their Partners
International Journal of Environmental Research and Public Health|2022
27 cit.

Current Senior Leaders

Established & currently active

Current Senior Leaders Researchers

1
Gregor B. E. Jemec
Gentofte Hospital
2
Errol P. Prens
Erasmus MC
3
Jacek C. Szepietowski
Wroclaw Medical University
4
Sylvie Bastuji‐Garin
Inserm
5
Alexa B. Kimball
Beth Israel Deaconess Medical Center
6
Christos C. Zouboulis
Freie Universität Berlin
7
Robert Sabat
Humboldt-Universität zu Berlin
8
Robert E. Hunger
University of Bern
9
James G. Krueger
Rockefeller University
10
Falk G. Bechara
Hidradenitis Suppurativa Foundation

Current Senior Leaders Papers

1
Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme
Archives of Dermatology|1993
1.6k cit.
2
IL-22 Increases the Innate Immunity of Tissues
Immunity|2004
1.3k cit.
3
SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis
Journal of Investigative Dermatology|2000
1.2k cit.
4
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Journal of the European Academy of Dermatology and Venereology|2015
1.1k cit.
5
Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
Journal of Investigative Dermatology|2008
1.1k cit.
6
IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis
European Journal of Immunology|2006
910 cit.
7
Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris
The Journal of Experimental Medicine|2004
892 cit.
8
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Journal of the American Academy of Dermatology|2017
860 cit.
9
Skin anti-aging strategies
Dermato-Endocrinology|2012
813 cit.
10
Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways
British Journal of Dermatology|2008
799 cit.

Reagents for Hidradenitis Suppurativa and Treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

🌟 All-Time

Most validated

Cell Signaling Technology

GKAP Antibody

#13602$317
View Evidence →